Therapeutic Mechanism of Baicalin in Experimental Colitis Analyzed Using Network Pharmacology and Metabolomics
Qi Wu,Xingxing Wu,Mao Wang,Kexin Liu,Yuge Li,Xiaoyu Ruan,Lin Qian,Lingchang Meng,Zhiting Sun,Lei Zhu,Jing Wu,Genglin Mu
DOI: https://doi.org/10.2147/DDDT.S399290
2023-04-01
Abstract:Qi Wu, 1, &ast Xingxing Wu, 1, &ast Mao Wang, 2, &ast Kexin Liu, 1 Yuge Li, 1 Xiaoyu Ruan, 1 Lin Qian, 1 Lingchang Meng, 3 Zhiting Sun, 3 Lei Zhu, 1 Jing Wu, 3 Genglin Mu 3 1 Gastroenterology Department, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; 2 Ethics Committee, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; 3 Institute of Chinese Medicine, Nanjing University, Nanjing Drum Tower Hospital, Drum Tower Clinical Medicine College of Nanjing University of Chinese Medicine, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jing Wu; Genglin Mu, Nanjing Drum Tower Hospital, Drum Tower Clinical Medicine College of the Nanjing University of Chinese Medicine, 321, Zhongshan Road, Nanjing, Jiangsu, People's Republic of China, Tel +86 13451825475, Email ; Background: Baicalin is an important active flavonoid isolated from the roots of Scutellaria baicalensis (S. baicalensis), a well-known traditional Chinese herb used in treating inflammatory bowel disease (IBD). The objectives of this study were to assess the potential benefit of baicalin in experimental colitis, as well as to investigate metabolic biomarkers of experimental colitis in conjunction with network pharmacology. Methods: Using a widely utilized network pharmacology technique, baicalin's targets and pathways were predicted. Simultaneously, experimental colitis was induced by intrarectal administration of TNBS. Histopathology examinations were performed to confirm pathological changes. Plasma samples were examined by using an untargeted metabolomics technique based on ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS) to screen differential metabolites and associated metabolic pathways. Additionally, network pharmacology and integrated analysis of metabolomics were used to identify the primary targets. Results: Through network pharmacology research, tumor necrosis factor (TNF), interleukin 6 (IL6), serine/threonine-protein kinase (AKT1), and other 7 proteins were found to be the main targets of baicalin against IBD. The untargeted metabolomics results showed that 47 metabolites in glycerophospholipids and sphingolipid metabolism were involved as key pathways in the experimental colitis model group. 19 metabolites, including Sphingomyelin (SM d42:2, SM d42:1, SM d34:1), Lysophosphatidic acids (LPA 18:4), 1-Palmitoylglycerophosphocholine, and 17(18)-EpETE were demonstrated as key metabolites for baicalin to exert effects. Moreover, udp-glucose ceramide glucosyltransferase (UGCG), sphingomyelin synthase 1 (SGMS1), and sphingosine kinase (SPHK1) were predicted as sphingolipids-linked targets of baicalin against experimental colitis by integrative analysis. Conclusion: Based on these results, it implies that sphingolipid metabolism and sphingolipid signaling pathway might be acted as therapeutic mechanism for baicalin against experimental colitis. Keywords: baicalin, inflammatory bowel disease, sphingolipid metabolism, metabolomics, network pharmacology, inflammation Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and Ulcerative colitis (UC) are chronic, idiopathic gastrointestinal (GI) diseases. It is thought to be the result of a complex interaction between a genetic predisposition and an abnormal host immune response to environmental exposures. The study of IBD has made extensive use of metabolomic techniques, which have the potential to be applied to disease subtyping and the evaluation of therapy response as well as offering insights into the pathophysiology of the disease. 1 Changes in the amino-acid and lipids metabolism have been observed in metabolic studies of IBD. 2 A lipid profile study in patients with IBD showed that primary bile acid biosynthesis, arachidonic acid metabolism, sphingolipid metabolism, fatty acid elongation, and glycerophospholipid metabolism were all linked to IBD dysregulation. 3,4 IBD treatment options currently available are relatively restricted, and they are mostly aimed at keeping the disease under control and maintaining remission. 5 However, this has to be weighed against the side effect profiles and costs of different drugs. With the advancement of high-throughput screening and bioinformatics technologies, natural products with a variety of pharmacological targets in different diseases have turned into important sources of novel drug discovery. These compounds are obtained from -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal